IOBT News and Press, IO Biotech Inc. From 09/06/23

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences: Event:...

2023-08-14 08:31:57 ET United States Steel  ( X ) +28% explores strategic alternatives after rejecting Cleveland-Cliffs offer . AMC Entertainment Holdings ( APE ) +25% . Genius Group  ( GNS ) +21% . Eloxx Pharmaceuticals ( ELOX ) +26% r ...

2023-08-11 10:44:55 ET IO Biotech press release ( NASDAQ: IOBT ): Q2 GAAP EPS of -$0.74. Cash and cash equivalents as of June 30, 2023 were $110.1 million, compared to $142.6 million at December 31, 2022. For further details see: IO Biotech GAAP EPS of -$0.74

Achieved significant enrollment milestone in pivotal Phase 3 trial of IO102-IO103 cancer vaccine in advanced melanoma; full enrollment anticipated by the end of 2023 Initiated enrollment in three investigator-initiated trials which the company is supporting to evaluate IO102-IO103 in combinat...

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win ® technology platform, announced the appointment of Heidi Hunter to its board of directors. Ms. Hunter,...

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract related to the company’s Phase 2 basket trial of ...

2023-08-07 08:53:52 ET IO Biotech Inc. ( NASDAQ: IOBT ) on Monday announced $75 million private placement financing. Under the agreement, the investors have agreed to purchase 37.07M shares of the company’s common stock and accompanying warrants to purchase up to an agg...

Offering includes participation from both new and existing healthcare-dedicated investors Proceeds extend the company’s cash runway into the fourth quarter of 2025 NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company de...

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win ® technology platform, announced today that the University of California Davis Comprehensive Cancer Cen...

NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract related to the company’s Phase 2 basket trial (IO...